Kathryne Kirk


The Myth of Skyrocketing Drug Prices: A Closer Look at The US Gross to Net Problem

While there has been an increase in discourse concerning drug pricing transparency in recent years, there is still a degree of misunderstanding. This is due to the healthcare industry's numerous stakeholders and their compelling interests. This research done by Guidehouse aims to clear the picture.